Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH MM 2018 | Double-blind trial of denosumab vs. zoledronic acid for bone disease in NDMM

Evangelos Terpos, MD, PhD, of the University of Athens, Athens, Greece, discusses the Phase II study of denosumab vs. zoledronic acid for the treatment of bone disease in newly diagnosed multiple myeloma (MM; NCT01345019). Dr Terpos expresses his excitement about the findings, particularly due to their double-blinded nature. This interview took place at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.